Skip to main content

Ritalin

(methylphenidate hydrochloride, immediate-release)

Ritalin (methylphenidate hydrochloride, immediate-release); CII

Full Prescribing Information DailyMed Drug Information

Summary

Ritalin is the immediate-release methylphenidate tablet, approved for ADHD in patients 6 years and older and for narcolepsy, and it is the reference product from which every long-acting methylphenidate is converted. Its short, sharply defined window is both its use and its cost: reversible within an afternoon and easy to schedule around, at the price of multiple daily dosing and a visible offset. Schedule II; brand and generic.

Forms & Strengths

  • Tablets (10 mg and 20 mg partially bisected, 5 mg not scored): 5 mg, 10 mg, 20 mg

Dosing

  • Age:
    • ADHD: >= 6y, and adults
    • Narcolepsy: no age floor
  • Onset: ~ 1 hour
  • Duration: 3 to 4 hours
  • Initial Dose:
    • >= 6 y/o and older: 5 mg twice daily, before breakfast and before lunch
    • Adults: 20 to 30 mg daily in 2 or 3 divided doses, 30 to 45 minutes before meals.
  • Titration: 5 - 10 mg every 7 days
  • Max Dose: 60 mg/day
  • Considerations: Give 30 to 45 minutes before meals, and the last dose before 6 p.m. The offset is abrupt and visible, which is the trade-off against every long-acting product.

Pharmacology

  • Mechanism: Blocks presynaptic dopamine and norepinephrine reuptake at DAT and NET; does not meaningfully promote catecholamine release at therapeutic doses
  • Delivery / Release: Immediate release. Absolute bioavailability 22% d-enantiomer, 5% l-enantiomer; first-pass loss is large and stereoselective. No relevant food effect.
  • Metabolism: Esterase de-esterification to ritalinic acid, inactive. Not a CYP substrate. Protein binding 10% to 33%. Half-life 2.5 h in children, 3.5 h in adults; under 1% excreted unchanged.
  • Class Positioning: The reference immediate-release methylphenidate, and the product every long-acting conversion table is written from. Esterase clearance means renal and hepatic impairment barely change exposure, and elimination is not pH-dependent.

Indications

  • ADHD (ICD-10: F90.0, F90.1, F90.2, F90.8, F90.9): patients 6 y/o and older, and adults
  • Narcolepsy (ICD-10: G47.419): no age floor is stated in this label

Off-Label Uses

  • ADHD in children 4 to 5 years old (ICD-10: F90.x): behavioral parent training first line; IR methylphenidate where it fails and disturbance stays moderate to severe. Expert consensus. (AAP 2019)
  • Afternoon top-up alongside a long-acting methylphenidate (ICD-10: F90.x): coherent given the 3 to 4 hour window; the 60 mg/day ceiling applies to the sum. Limited data. (AHRQ 2024)
  • Where the evidence does not support use: treatment-resistant depression (F33.9), binge eating disorder (F50.2), cancer-related and chronic fatigue (R53.0, R53.83). Adult literature only; insufficient in children. (AHRQ 2024)
  • Cognitive enhancement in a youth without ADHD: not an indication and not supported.

Contraindications & Warnings

  • Boxed Warning: Abuse, misuse and addiction, with overdose and death. Assess abuse risk before prescribing and reassess throughout treatment.
  • Contraindicated:
    • Hypersensitivity to methylphenidate or any component
    • MAOI use, current or within 14 days: hypertensive crisis
  • Use with caution:
    • Structural cardiac abnormality, cardiomyopathy, arrhythmia or coronary disease: avoid
    • Pre-existing hypertension: monitor blood pressure and pulse
    • Psychotic or bipolar disorder: exacerbation and treatment-emergent mania
    • Significant hyperopia or angle-closure risk: refer to ophthalmology
    • Personal or family history of tics or Tourette's syndrome
    • Substance use disorder in patient or household; an IR tablet is the most divertible methylphenidate form
  • Screen before starting:
    • Cardiac history and exam including family sudden death; the label requires no routine ECG
    • Tics, and risk factors for a manic episode
    • Abuse and diversion risk in patient and household
    • Baseline height, weight, blood pressure and heart rate

Drug Interactions

  • MAOIs (phenelzine, tranylcypromine, selegiline, linezolid, methylene blue): hypertensive crisis. Contraindicated within 14 days.
  • Antihypertensives: effectiveness reduced. Increase BP monitoring and adjust the antihypertensive.
  • Halogenated anesthetics (sevoflurane, isoflurane, desflurane): intraoperative BP and HR surge. Hold every dose on the day of surgery, not just the morning one.
  • Risperidone: EPS may increase when either dose changes in either direction. Monitor across any titration.
  • Serotonergic agents (SSRIs, SNRIs, TCAs, triptans, tramadol): serotonin syndrome in postmarketing reports only, not in the interaction table. Counsel on symptoms.

Administration

  • Give 30 to 45 minutes before meals, which is a labeled instruction.
  • Before breakfast and before lunch; add a third dose for afternoon coverage.
  • Last dose before 6 p.m. for anyone whose sleep is affected.
  • Food has no relevant effect on absorption; a missed meal is not a reason to hold a dose.
  • The 5 mg tablet is not scored; a sub-5 mg step needs the 2.5 mg chewable or the oral solution (Methylin).
  • Missed dose: give only if the next is several hours away and it is not late. Never double up.
  • Converting to a long-acting product (Ritalin LA, Metadate CD, Concerta): never match milligrams; use that product's conversion table.
  • Store locked; an IR tablet is the methylphenidate form most often diverted.

Side Effects

  • Common: tachycardia, palpitations, headache, insomnia, anxiety, hyperhidrosis, weight loss, decreased appetite, dry mouth, nausea, abdominal pain. No pediatric percentages published.
  • Serious:
    • Sudden death with structural cardiac disease: avoid the drug in that population
    • New psychosis or mania, including with no psychiatric history: consider discontinuing
    • Priapism, sometimes surgical, typically after a dose increase and also during drug holidays
    • Peripheral vasculopathy and Raynaud's with digital ulceration: assess digits each visit
    • Long-term growth suppression; acute angle closure glaucoma; new or worsening tics and Tourette's
    • Postmarketing: convulsions, choreoathetoid dyskinesia, cerebral vasculitis and hemorrhage, serotonin syndrome
    • Rebound irritability, hunger and tearfulness at each offset, two or three times a day: an offset effect, not an adverse reaction

Monitoring & Labs

  • Cardiovascular: BP and HR at baseline, at every dose change, and at least every 6 months. Tachycardia and palpitations head this label's reaction list.
  • Growth: height, weight and BMI at baseline and every 6 months; failure to gain triggers interruption.
  • Appetite and sleep: at every visit and dose change; ask what time the last dose is given.
  • Adherence: confirm at every visit that the midday dose is given; a missed school dose mimics loss of efficacy.
  • Psychiatric and tics: screen for psychosis, mania, aggression, depressed mood and tics at baseline and every visit.
  • Abuse and diversion: at every refill, count the tablets rather than accepting a report, ask about sharing and selling, check the PDMP. A boxed-warning obligation.
  • Laboratory: none is required by this label.

Discontinuation & Taper

  • No taper required; the label gives no tapering schedule.
  • Discontinue if no improvement after appropriate dose adjustment over one month.
  • Withdrawal after prolonged use: dysphoria, fatigue, vivid dreams, sleep change, increased appetite.
  • Priapism has occurred during drug holidays and on discontinuation.
  • Partial drug holidays are possible here: school days only, or a morning dose only at weekends. That granularity is the IR tablet's main advantage where growth limits treatment.

Pregnancy & Lactation

  • Pregnancy: no drug-associated risk of major birth defects or miscarriage identified. Stimulant vasoconstriction may reduce placental perfusion. Weigh against untreated maternal ADHD or narcolepsy.
  • Lactation: infant dose 0.16% to 0.7% of the maternal weight-adjusted dose; undetectable in infant plasma in every reported case, including 40 mg twice daily. Not a reason to stop breastfeeding. (LactMed 2025)
  • Lactation, milk supply: prolactin falls; large doses may interfere before supply is established. Monitor the infant for agitation, insomnia and poor weight gain. (LactMed 2025)
  • Exposure Registry: National Pregnancy Registry for ADHD Medications, 1-866-961-2388, womensmentalhealth.org/adhd-medications.

Counseling Points

  • Counsel the family on:

    • The 3 to 4 hour window: the lunchtime dose is part of the plan, not a sign the first failed.
    • Dosing 30 to 45 minutes before a meal, keeping the appetite trough between meals.
    • The last dose being before 6 p.m.; a 7 p.m. dose costs that night's sleep.
    • Rebound irritability and hunger two or three times a day: expected, not a reason to raise the dose.
    • Arranging the school dose before the first prescription is filled: nurse-administered, self-carry, or switch to a long-acting product.
    • The 5 mg tablet not being scored; a smaller step means a chewable or the solution, not a cut tablet.
    • Locked storage; sharing or selling a Schedule II medication is a felony, and the IR tablet is what peers ask for.
    • Bringing a teacher rating scale that separates morning from afternoon.

  • Advise them to call for:

    • Chest pain, fainting, or a racing heart that does not settle.
    • New hallucinations, or new suspicious or fearful thinking.
    • Numbness, coldness or colour change in fingers or toes, or a sore that will not heal.
    • A new or markedly worse tic, including throat clearing and blinking.
    • A painful erection lasting more than a few hours, including during a planned break.
    • Any seizure, or a jerking movement the child cannot stop.
    • Eye pain with blurred vision or halos around lights.
    • Clothes fitting more loosely, or no weight gain across a few months.

References

  1. DailyMed. Ritalin (methylphenidate hydrochloride) tablets prescribing information. Novartis Pharmaceuticals Corporation. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a
  2. FDA. openFDA National Drug Code Directory, generic_name methylphenidate. 2026. https://api.fda.gov/drug/ndc.json?search=generic_name:%22methylphenidate%22&limit=1000
  3. LactMed. Methylphenidate. Drugs and Lactation Database, NICHD. 2025. https://www.ncbi.nlm.nih.gov/books/NBK501310/
  4. American Academy of Pediatrics. Clinical practice guideline for the diagnosis, evaluation, and treatment of ADHD in children and adolescents. Pediatrics. 2019. https://publications.aap.org/pediatrics/article/144/4/e20192528/81590/
  5. AHRQ. Attention deficit hyperactivity disorder: diagnosis and treatment in children and adolescents. Comparative Effectiveness Review No. 267. 2024. https://www.ncbi.nlm.nih.gov/books/NBK602989/
Back to top